---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-304330"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:51:29.037571+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kymera reports positive KT-474 Phase 1 data; Sanofi advances to Phase 2; oncology programs show target knockdown

## Summary
- KT-474 achieved >90% IRAK4 degradation in blood and skin; cytokine inhibition up to 98% in AD and 84% in HS; no serious AEs.
- Sanofi committed to Phase 2 trials for KT-474 in HS and AD, with first study starting in 2023.
- KT-413 (IRAKIMiD) showed up to 100% Ikaros/Aiolos knockdown and 40% IRAK4 knockdown at dose level 2; no DLTs.
- KT-333 (STAT3) showed mean 66% STAT3 degradation (up to 86%) in PBMC at dose level 1; dose level 2 enrolling.
- FDA cleared IND for KT-253 (MDM2 degrader); Phase 1 planned for early 2023.

## SEC filing metadata
- accession: 0001193125-22-304330
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312522304330/0001193125-22-304330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312522304330/d429465d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-304330
- JSON: https://secwatch.observer/filing/0001193125-22-304330.json
- Plain text: https://secwatch.observer/filing/0001193125-22-304330.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.